Q2 2026 Pelthos Therapeutics Inc Earnings Call Transcript
Key Points
- Strong revenue growth with net product revenue increasing 45% quarter-over-quarter to $15.4 million in Q2 2026.
- Prescription units rose 48% from Q1 to Q2, with over 30,000 units dispensed since launch.
- High commercial insurance coverage at 59% and 100% Medicaid coverage for ZELSUVMI.
- Positive expert consensus guidelines published in JDD support ZELSUVMI as a first-line at-home treatment for molluscum contagiosum.
- Successful PBM contract led to an 81.3% increase in units dispensed and 68% increase in prescribers within that PBM.
- Restatement of Q1 2026 financials due to misapplication of fair value accounting for convertible debt, creating uncertainty.
- Cost of goods sold increased significantly to $3.6 million in Q2, including a $0.9 million write-off of API inventory.
- SG&A expenses rose 31% quarter-over-quarter, driven by a $5.3 million one-time sales milestone and higher royalties.
- Cash position decreased to $24.2 million from $44.8 million in working capital, raising concerns about runway.
- Gross-to-net rates are expected to rise to mid-30% range, potentially impacting future revenue.
Greetings, and welcome to the Q2 2026 Pelthos Therapeutics Inc Conference Call.
(Operator Instructions)
I would now like to turn the conference over to your host, Mike Moyer of LifeSci Advisors. You may begin.
Good morning, everyone, and welcome to Pelthos Therapeutics Inc 2026 Second Quarter Financial Results Conference Call.
Pelthos issued a press release today announcing its financial results for the quarter ended June 30, 2026. A copy can be found in the Investor Relations tab on the company's corporate website at www.Pelthos.com. Before we begin, I'd like to remind you that during today's call, statements about the company's future expectations, projections, plans, and prospects are forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
